Clinical Trials


Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting

This study has been completed
Solvay Pharmaceuticals

Information provided by (Responsible Party)
Solvay Pharmaceuticals Identifier

First received: March 21, 2008
Last updated: April 1, 2008
Last Verified: March 2008
History of Changes


The primary purpose of this study is to determine if dronabinol is effective in preventing or treating nausea caused by HAART (highly active anti-retroviral therapy) in HIV and AIDS patients

Condition Intervention Phase
Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting
HIV Infections

Drug : Dronabinol
Drug : Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Parallel-Group, Pilot Study of Oral Dronabinol Versus Placebo in the Treatment or Prevention of Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting

Further study details as provided by Solvay Pharmaceuticals:

Primary Outcome Measures

  • The absence of nausea as indicated by a visual analog scale (VAS) score < 5 mm [ Time Frame: 2 weeks ]
Secondary Outcome Measures:
  • Number of episodes vomiting/retching [ Time Frame: 2 weeks ]
  • Duration of nausea, vomiting/retching [ Time Frame: 2 weeks ]
  • Intensity of nausea by VAS [ Time Frame: 2 weeks ]
  • Appetite stimulation by VAS [ Time Frame: 2 weeks ]

Enrollment: 103
Study Start Date: August 2003
Study Completion Date: April 2005
Primary Completion Date: April 2005 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: 1

Drug: Dronabinol

2.5 mg to 40 mg

Placebo Comparator: 2

Drug: Placebo




Ages Eligible for Study: 18 Years to 70 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria:

  • Adherence to prior or current HAART was or is being compromised, or HAART was discontinued/interrupted due to nausea/vomiting; or beginning HAART or switching from a regimen at the time of screening for this study that did not produce significant nausea and/or vomiting to a regimen with zidovudine or a protease inhibitor (with or without low dose ritonavir).

Exclusion Criteria:
  • Subjects with recent (within 30 days of randomization) or current opportunistic
infection or neoplasm characteristic of AIDS (Category C of the CDC Classification System for HIV-1 infection, 1993 Revised Version).

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00642499


United States, California
Site 911
Bakersfield, California, United States
Site 919
Fresno, California, United States
Site 924
Los Angeles, California, United States
Site 932
Los Angeles, California, United States
Site 926
Palm Springs, California, United States
Site 946
Pasadena, California, United States
Site 913
Tarzana, California, United States
United States, Florida
Site 907
Altamonte Springs, Florida, United States
Site 948
Miami, Florida, United States
Site 951
Miami, Florida, United States
Site 953
Miami, Florida, United States
Site 959
Miami, Florida, United States
Site 954
N. Palm Beach, Florida, United States
Site 957
Pensacola, Florida, United States
Site 923
Port St. Lucie, Florida, United States
Site 929
Sarasota, Florida, United States
Site 952
Tallahassee, Florida, United States
Site 931
Tampa, Florida, United States
United States, Georgia
Site 908
Decatur, Georgia, United States
United States, Idaho
Site 905
Boise, Idaho, United States
United States, Illinois
Site 914
Chicago, Illinois, United States
United States, Kentucky
Site 928
Louisville, Kentucky, United States
Site 955
Louisville, Kentucky, United States
United States, Louisiana
Site 958
New Orleans, Louisiana, United States
United States, Massachusetts
Site 934
Boston, Massachusetts, United States
United States, Missouri
Site 915
Springfield, Missouri, United States
United States, New Jersey
Site 956
Somers Point, New Jersey, United States
United States, New York
Site 921
Albany, New York, United States
United States, Ohio
Site 910
Cincinnati, Ohio, United States
United States, Pennsylvania
Site 941
Philadelphia, Pennsylvania, United States
United States, Texas
Site 925
Dallas, Texas, United States
Site 917
Fort Worth, Texas, United States
Site 906
Houston, Texas, United States
Site 942
Houston, Texas, United States
United States, Washington
Site 909
Tacoma, Washington, United States
Site 927
Vancouver, Washington, United States

Sponsors and Collaborators

Solvay Pharmaceuticals


Study Director: Global Clinical Director Solvay Solvay Pharmaceuticals
More Information

More Information

Responsible Party: Vickie Baranowski, Solvay Pharmaceuticals Identifier: NCT00642499   History of Changes  
Other Study ID Numbers: S175.2.101  
Study First Received: March 21, 2008  
Last Updated: April 1, 2008  

Keywords provided by Solvay Pharmaceuticals:

Treatment Experienced
HIV Infections

Additional relevant MeSH terms:
HIV Infections
Dronabinol processed this data on September 24, 2018
This information is provided by